You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCholic Acid
Accession NumberDB02659  (EXPT00906)
TypeSmall Molecule
GroupsApproved
DescriptionA major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion. [PubChem] Cholic acid, formulated as Cholbam capsules, is approved by the United States Food and Drug Administration as a treatment for children and adults with bile acid synthesis disorders due to single enzyme defects, and for peroxisomal disorders (such as Zellweger syndrome).
Structure
Thumb
SynonymsNot Available
External Identifiers
  • E1000
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CholbamCapsule50 mg/1OralManchester Pharmaceuticals2015-03-31Not applicableUs
CholbamCapsule250 mg/1OralManchester Pharmaceuticals2015-03-31Not applicableUs
KolbamCapsule50 mgOralRetrophin Europe Ltd2015-11-20Not applicableEu
KolbamCapsule250 mgOralRetrophin Europe Ltd2015-11-20Not applicableEu
OrphacolCapsule250 mgOralLaboratoires Ctrs2013-09-12Not applicableEu
OrphacolCapsule50 mgOralLaboratoires Ctrs2013-09-12Not applicableEu
OrphacolCapsule250 mgOralLaboratoires Ctrs2013-09-12Not applicableEu
OrphacolCapsule50 mgOralLaboratoires Ctrs2013-09-12Not applicableEu
OrphacolCapsule250 mgOralLaboratoires Ctrs2013-09-12Not applicableEu
OrphacolCapsule50 mgOralLaboratoires Ctrs2013-09-12Not applicableEu
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIG1JO7801AE
CAS number81-25-4
WeightAverage: 408.5714
Monoisotopic: 408.28757439
Chemical FormulaC24H40O5
InChI KeyBHQCQFFYRZLCQQ-OELDTZBJSA-N
InChI
InChI=1S/C24H40O5/c1-13(4-7-21(28)29)16-5-6-17-22-18(12-20(27)24(16,17)3)23(2)9-8-15(25)10-14(23)11-19(22)26/h13-20,22,25-27H,4-12H2,1-3H3,(H,28,29)/t13-,14+,15-,16-,17+,18+,19-,20+,22+,23+,24-/m1/s1
IUPAC Name
(4R)-4-[(1S,2S,5R,7S,9R,10R,11S,14R,15R,16S)-5,9,16-trihydroxy-2,15-dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadecan-14-yl]pentanoic acid
SMILES
[H][C@@](C)(CCC(O)=O)[C@@]1([H])CC[C@@]2([H])[C@]3([H])[C@]([H])(O)C[C@]4([H])C[C@]([H])(O)CC[C@]4(C)[C@@]3([H])C[C@]([H])(O)[C@]12C
Pharmacology
IndicationOral cholic acid is indicated for: treatment of bile acid synthesis disorders due to single enzyme defects; and as adjunctive treatment of peroxisomal disorders including Zellweger spectrum disorders in patients who exhibit manifestations of liver disease, steatorrhea or complications from decreased fat soluble vitamin absorption.
Structured Indications
PharmacodynamicsNot Available
Mechanism of action
TargetKindPharmacological actionActionsOrganismUniProt ID
Ferrochelatase, mitochondrialProteinunknownNot AvailableHumanP22830 details
Alcohol dehydrogenase 1CProteinunknownNot AvailableHumanP00326 details
Estrogen-related receptor gammaProteinunknownNot AvailableHumanP62508 details
GastrotropinProteinunknownNot AvailableHumanP51161 details
Cytochrome c oxidase subunit 4 isoform 1, mitochondrialProteinunknownNot AvailableHumanP13073 details
Cytochrome c oxidase subunit 1ProteinunknownNot AvailableHumanP00395 details
Cytochrome c oxidase subunit 2ProteinunknownNot AvailableHumanP00403 details
Cytochrome c oxidase subunit 3ProteinunknownNot AvailableHumanP00414 details
Cytochrome c oxidase subunit 5A, mitochondrialProteinunknownNot AvailableHumanP20674 details
Cytochrome c oxidase subunit 5B, mitochondrialProteinunknownNot AvailableHumanP10606 details
Cytochrome c oxidase subunit 6CProteinunknownNot AvailableHumanP09669 details
Cytochrome c oxidase subunit 7B, mitochondrialProteinunknownNot AvailableHumanP24311 details
Cytochrome c oxidase subunit 7C, mitochondrialProteinunknownNot AvailableHumanP15954 details
Cytochrome c oxidase subunit 8A, mitochondrialProteinunknownNot AvailableHumanP10176 details
Cytochrome c oxidase subunit 6A2, mitochondrialProteinunknownNot AvailableHumanQ02221 details
Cytochrome c oxidase subunit 6B1ProteinunknownNot AvailableHumanP14854 details
Cytochrome c oxidase subunit 7A1, mitochondrialProteinunknownNot AvailableHumanP24310 details
Phospholipase A2ProteinunknownNot AvailableHumanP04054 details
Liver carboxylesterase 1ProteinunknownNot AvailableHumanP23141 details
FerrochelataseProteinunknownNot AvailableHumanQ7KZA3 details
Choloylglycine hydrolaseProteinunknownNot AvailableClostridium perfringens (strain 13 / Type A)P54965 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism
SubstrateEnzymesProduct
Cholic Acid
Not Available
Cholic acid glucuronideDetails
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
Pathways
PathwayCategorySMPDB ID
Cerebrotendinous Xanthomatosis (CTX)DiseaseSMP00315
27-Hydroxylase DeficiencyDiseaseSMP00720
Bile Acid BiosynthesisMetabolicSMP00035
Familial Hypercholanemia (FHCA)DiseaseSMP00317
Congenital Bile Acid Synthesis Defect Type IIDiseaseSMP00314
Zellweger SyndromeDiseaseSMP00316
Congenital Bile Acid Synthesis Defect Type IIIDiseaseSMP00318
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcebutololThe serum concentration of Acebutolol can be decreased when it is combined with Cholic Acid.Approved
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Cholic Acid.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be decreased when it is combined with Cholic Acid.Approved, Vet Approved
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Cholic Acid.Approved
AldosteroneThe serum concentration of Aldosterone can be decreased when it is combined with Cholic Acid.Experimental
AlitretinoinThe serum concentration of Alitretinoin can be decreased when it is combined with Cholic Acid.Approved, Investigational
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Cholic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AmbrisentanThe serum concentration of Ambrisentan can be decreased when it is combined with Cholic Acid.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be decreased when it is combined with Cholic Acid.Approved
ApixabanThe serum concentration of Apixaban can be decreased when it is combined with Cholic Acid.Approved
Arsenic trioxideThe serum concentration of Arsenic trioxide can be decreased when it is combined with Cholic Acid.Approved, Investigational
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Cholic Acid.Approved, Investigational
AtenololThe serum concentration of Atenolol can be decreased when it is combined with Cholic Acid.Approved
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Cholic Acid.Approved, Investigational
BetamethasoneThe serum concentration of Betamethasone can be decreased when it is combined with Cholic Acid.Approved, Vet Approved
BoceprevirThe serum concentration of Boceprevir can be decreased when it is combined with Cholic Acid.Approved
BosentanBosentan may decrease the excretion rate of Cholic Acid which could result in a higher serum level.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Cholic Acid.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Cholic Acid.Approved
BromocriptineThe serum concentration of Bromocriptine can be decreased when it is combined with Cholic Acid.Approved, Investigational
CabazitaxelThe serum concentration of Cabazitaxel can be decreased when it is combined with Cholic Acid.Approved
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Cholic Acid.Approved
CamptothecinThe serum concentration of Camptothecin can be decreased when it is combined with Cholic Acid.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be decreased when it is combined with Cholic Acid.Approved
CarbamazepineThe serum concentration of Carbamazepine can be decreased when it is combined with Cholic Acid.Approved, Investigational
CarfilzomibThe serum concentration of Carfilzomib can be decreased when it is combined with Cholic Acid.Approved
CeritinibThe serum concentration of Ceritinib can be decreased when it is combined with Cholic Acid.Approved
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Cholic Acid.Withdrawn
ChlorpromazineChlorpromazine may decrease the excretion rate of Cholic Acid which could result in a higher serum level.Approved, Vet Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Cholic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CimetidineCimetidine may decrease the excretion rate of Cholic Acid which could result in a higher serum level.Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be decreased when it is combined with Cholic Acid.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be decreased when it is combined with Cholic Acid.Approved
CitalopramThe serum concentration of Citalopram can be decreased when it is combined with Cholic Acid.Approved
ClarithromycinThe serum concentration of Clarithromycin can be decreased when it is combined with Cholic Acid.Approved
ClobazamThe serum concentration of Clobazam can be decreased when it is combined with Cholic Acid.Approved, Illicit
ClofazimineClofazimine may decrease the excretion rate of Cholic Acid which could result in a higher serum level.Approved, Investigational
ClomifeneThe serum concentration of Clomifene can be decreased when it is combined with Cholic Acid.Approved, Investigational
ClonidineThe serum concentration of Clonidine can be decreased when it is combined with Cholic Acid.Approved
ClopidogrelThe serum concentration of Clopidogrel can be decreased when it is combined with Cholic Acid.Approved, Nutraceutical
ClozapineThe serum concentration of Clozapine can be decreased when it is combined with Cholic Acid.Approved
CobimetinibThe serum concentration of Cobimetinib can be decreased when it is combined with Cholic Acid.Approved
ColchicineThe serum concentration of Colchicine can be decreased when it is combined with Cholic Acid.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Cholic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Cholic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Cholic Acid.Approved
CrizotinibThe serum concentration of Crizotinib can be decreased when it is combined with Cholic Acid.Approved
CyclosporineCyclosporine may decrease the excretion rate of Cholic Acid which could result in a higher serum level.Approved, Investigational, Vet Approved
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Cholic Acid.Approved
DabrafenibThe serum concentration of Dabrafenib can be decreased when it is combined with Cholic Acid.Approved
DactinomycinThe serum concentration of Dactinomycin can be decreased when it is combined with Cholic Acid.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be decreased when it is combined with Cholic Acid.Approved
DasatinibThe serum concentration of Dasatinib can be decreased when it is combined with Cholic Acid.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be decreased when it is combined with Cholic Acid.Approved
DebrisoquinThe serum concentration of Debrisoquin can be decreased when it is combined with Cholic Acid.Approved
DexamethasoneThe serum concentration of Dexamethasone can be decreased when it is combined with Cholic Acid.Approved, Investigational, Vet Approved
DiazepamThe serum concentration of Diazepam can be decreased when it is combined with Cholic Acid.Approved, Illicit, Vet Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Cholic Acid.Approved
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Cholic Acid.Approved
DigoxinThe serum concentration of Digoxin can be decreased when it is combined with Cholic Acid.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be decreased when it is combined with Cholic Acid.Illicit
DiltiazemThe serum concentration of Diltiazem can be decreased when it is combined with Cholic Acid.Approved
DipyridamoleThe serum concentration of Dipyridamole can be decreased when it is combined with Cholic Acid.Approved
DocetaxelThe serum concentration of Docetaxel can be decreased when it is combined with Cholic Acid.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be decreased when it is combined with Cholic Acid.Approved, Investigational, Vet Approved
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Cholic Acid.Approved, Investigational
EdoxabanThe serum concentration of Edoxaban can be decreased when it is combined with Cholic Acid.Approved
EletriptanThe serum concentration of Eletriptan can be decreased when it is combined with Cholic Acid.Approved, Investigational
EltrombopagThe serum concentration of Cholic Acid can be increased when it is combined with Eltrombopag.Approved
EpinastineThe serum concentration of Epinastine can be decreased when it is combined with Cholic Acid.Approved, Investigational
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Cholic Acid.Approved, Investigational
ErythromycinThe serum concentration of Erythromycin can be decreased when it is combined with Cholic Acid.Approved, Vet Approved
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Cholic Acid.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be decreased when it is combined with Cholic Acid.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be decreased when it is combined with Cholic Acid.Approved
Ethinyl EstradiolEthinyl Estradiol may decrease the excretion rate of Cholic Acid which could result in a higher serum level.Approved
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Cholic Acid.Approved
EzetimibeThe serum concentration of Ezetimibe can be decreased when it is combined with Cholic Acid.Approved
FesoterodineThe serum concentration of Fesoterodine can be decreased when it is combined with Cholic Acid.Approved
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Cholic Acid.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be decreased when it is combined with Cholic Acid.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be decreased when it is combined with Cholic Acid.Approved
Fusidic AcidFusidic Acid may decrease the excretion rate of Cholic Acid which could result in a higher serum level.Approved
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Cholic Acid.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be decreased when it is combined with Cholic Acid.Approved
GlyburideGlyburide may decrease the excretion rate of Cholic Acid which could result in a higher serum level.Approved
Glycochenodeoxycholic AcidGlycochenodeoxycholic Acid may decrease the excretion rate of Cholic Acid which could result in a higher serum level.Experimental
GrazoprevirThe serum concentration of Grazoprevir can be decreased when it is combined with Cholic Acid.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Cholic Acid.Withdrawn
HaloperidolThe serum concentration of Haloperidol can be decreased when it is combined with Cholic Acid.Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Cholic Acid.Approved, Vet Approved
IbuprofenThe serum concentration of Ibuprofen can be decreased when it is combined with Cholic Acid.Approved
IdelalisibThe serum concentration of Idelalisib can be decreased when it is combined with Cholic Acid.Approved
ImatinibThe serum concentration of Imatinib can be decreased when it is combined with Cholic Acid.Approved
ImipramineThe serum concentration of Imipramine can be decreased when it is combined with Cholic Acid.Approved
IndacaterolThe serum concentration of Indacaterol can be decreased when it is combined with Cholic Acid.Approved
IndinavirThe serum concentration of Indinavir can be decreased when it is combined with Cholic Acid.Approved
IndomethacinThe serum concentration of Indomethacin can be decreased when it is combined with Cholic Acid.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be decreased when it is combined with Cholic Acid.Approved, Investigational
IvermectinThe serum concentration of Ivermectin can be decreased when it is combined with Cholic Acid.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be decreased when it is combined with Cholic Acid.Approved
KetoconazoleKetoconazole may decrease the excretion rate of Cholic Acid which could result in a higher serum level.Approved, Investigational
LamivudineThe serum concentration of Lamivudine can be decreased when it is combined with Cholic Acid.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Cholic Acid.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be decreased when it is combined with Cholic Acid.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Cholic Acid.Approved
LenalidomideThe serum concentration of Lenalidomide can be decreased when it is combined with Cholic Acid.Approved
LenvatinibThe serum concentration of Lenvatinib can be decreased when it is combined with Cholic Acid.Approved
LevetiracetamThe serum concentration of Levetiracetam can be decreased when it is combined with Cholic Acid.Approved, Investigational
LevofloxacinThe serum concentration of Levofloxacin can be decreased when it is combined with Cholic Acid.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be decreased when it is combined with Cholic Acid.Approved
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Cholic Acid.Approved
LoperamideThe serum concentration of Loperamide can be decreased when it is combined with Cholic Acid.Approved
LosartanThe serum concentration of Losartan can be decreased when it is combined with Cholic Acid.Approved
MannitolThe serum concentration of Mannitol can be decreased when it is combined with Cholic Acid.Approved, Investigational
MethotrexateThe serum concentration of Methotrexate can be decreased when it is combined with Cholic Acid.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be decreased when it is combined with Cholic Acid.Approved, Vet Approved
MetoprololThe serum concentration of Metoprolol can be decreased when it is combined with Cholic Acid.Approved, Investigational
MidazolamThe serum concentration of Midazolam can be decreased when it is combined with Cholic Acid.Approved, Illicit
MirabegronThe serum concentration of Mirabegron can be decreased when it is combined with Cholic Acid.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be decreased when it is combined with Cholic Acid.Approved, Investigational
MorphineThe serum concentration of Morphine can be decreased when it is combined with Cholic Acid.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Cholic Acid.Approved, Investigational
NadololThe serum concentration of Nadolol can be decreased when it is combined with Cholic Acid.Approved
NaloxoneThe serum concentration of Naloxone can be decreased when it is combined with Cholic Acid.Approved, Vet Approved
NelfinavirThe serum concentration of Nelfinavir can be decreased when it is combined with Cholic Acid.Approved
NicardipineThe serum concentration of Nicardipine can be decreased when it is combined with Cholic Acid.Approved
NifedipineThe serum concentration of Nifedipine can be decreased when it is combined with Cholic Acid.Approved
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Cholic Acid.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Cholic Acid.Approved
NizatidineThe serum concentration of Nizatidine can be decreased when it is combined with Cholic Acid.Approved
NovobiocinNovobiocin may decrease the excretion rate of Cholic Acid which could result in a higher serum level.Approved, Vet Approved
OlanzapineThe serum concentration of Olanzapine can be decreased when it is combined with Cholic Acid.Approved, Investigational
OmbitasvirThe serum concentration of Ombitasvir can be decreased when it is combined with Cholic Acid.Approved
OsimertinibThe serum concentration of Osimertinib can be decreased when it is combined with Cholic Acid.Approved
PaclitaxelPaclitaxel may decrease the excretion rate of Cholic Acid which could result in a higher serum level.Approved, Vet Approved
PanobinostatThe serum concentration of Panobinostat can be decreased when it is combined with Cholic Acid.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Cholic Acid.Approved
PhenobarbitalThe serum concentration of Phenobarbital can be decreased when it is combined with Cholic Acid.Approved
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Cholic Acid.Approved, Vet Approved
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Cholic Acid.Approved
PomalidomideThe serum concentration of Pomalidomide can be decreased when it is combined with Cholic Acid.Approved
PonatinibPonatinib may decrease the excretion rate of Cholic Acid which could result in a higher serum level.Approved
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Cholic Acid.Approved
PrazosinThe serum concentration of Prazosin can be decreased when it is combined with Cholic Acid.Approved
PrednisoloneThe serum concentration of Prednisolone can be decreased when it is combined with Cholic Acid.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be decreased when it is combined with Cholic Acid.Approved, Vet Approved
ProgesteroneProgesterone may decrease the excretion rate of Cholic Acid which could result in a higher serum level.Approved, Vet Approved
PropranololThe serum concentration of Propranolol can be decreased when it is combined with Cholic Acid.Approved, Investigational
QuetiapineThe serum concentration of Quetiapine can be decreased when it is combined with Cholic Acid.Approved
QuinidineQuinidine may decrease the excretion rate of Cholic Acid which could result in a higher serum level.Approved
QuinineThe serum concentration of Quinine can be decreased when it is combined with Cholic Acid.Approved
RanitidineThe serum concentration of Ranitidine can be decreased when it is combined with Cholic Acid.Approved
ReserpineReserpine may decrease the excretion rate of Cholic Acid which could result in a higher serum level.Approved
RifampicinRifampicin may decrease the excretion rate of Cholic Acid which could result in a higher serum level.Approved
RisperidoneThe serum concentration of Risperidone can be decreased when it is combined with Cholic Acid.Approved, Investigational
RitonavirThe serum concentration of Ritonavir can be decreased when it is combined with Cholic Acid.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Cholic Acid.Approved
RomidepsinThe serum concentration of Romidepsin can be decreased when it is combined with Cholic Acid.Approved, Investigational
Salicylic acidThe serum concentration of Salicylic acid can be decreased when it is combined with Cholic Acid.Approved, Vet Approved
SaquinavirThe serum concentration of Saquinavir can be decreased when it is combined with Cholic Acid.Approved, Investigational
SelexipagThe serum concentration of Selexipag can be decreased when it is combined with Cholic Acid.Approved
SevelamerSevelamer can cause a decrease in the absorption of Cholic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SilodosinThe serum concentration of Silodosin can be decreased when it is combined with Cholic Acid.Approved
SimeprevirThe serum concentration of Simeprevir can be decreased when it is combined with Cholic Acid.Approved
SitagliptinThe serum concentration of Sitagliptin can be decreased when it is combined with Cholic Acid.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Cholic Acid.Approved
SorafenibThe serum concentration of Sorafenib can be decreased when it is combined with Cholic Acid.Approved, Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Cholic Acid.Approved
SphingosineThe serum concentration of Sphingosine can be decreased when it is combined with Cholic Acid.Experimental
SucralfateSucralfate can cause a decrease in the absorption of Cholic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TacrolimusThe serum concentration of Tacrolimus can be decreased when it is combined with Cholic Acid.Approved, Investigational
TamoxifenTamoxifen may decrease the excretion rate of Cholic Acid which could result in a higher serum level.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be decreased when it is combined with Cholic Acid.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Cholic Acid.Approved
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Cholic Acid.Approved
TemsirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Cholic Acid.Approved
TeriflunomideThe serum concentration of Cholic Acid can be increased when it is combined with Teriflunomide.Approved
TicagrelorThe serum concentration of Ticagrelor can be decreased when it is combined with Cholic Acid.Approved
TimololThe serum concentration of Timolol can be decreased when it is combined with Cholic Acid.Approved
TolvaptanThe serum concentration of Tolvaptan can be decreased when it is combined with Cholic Acid.Approved
TopotecanThe serum concentration of Topotecan can be decreased when it is combined with Cholic Acid.Approved, Investigational
ToremifeneThe serum concentration of Toremifene can be decreased when it is combined with Cholic Acid.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be decreased when it is combined with Cholic Acid.Approved
TroglitazoneTroglitazone may decrease the excretion rate of Cholic Acid which could result in a higher serum level.Withdrawn
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Cholic Acid.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be decreased when it is combined with Cholic Acid.Approved
Ursodeoxycholic acidUrsodeoxycholic acid may decrease the excretion rate of Cholic Acid which could result in a higher serum level.Approved, Investigational
VecuroniumThe serum concentration of Vecuronium can be decreased when it is combined with Cholic Acid.Approved
VenetoclaxThe serum concentration of Venetoclax can be decreased when it is combined with Cholic Acid.Approved
VenlafaxineThe serum concentration of Venlafaxine can be decreased when it is combined with Cholic Acid.Approved
VerapamilVerapamil may decrease the excretion rate of Cholic Acid which could result in a higher serum level.Approved
VinblastineVinblastine may decrease the excretion rate of Cholic Acid which could result in a higher serum level.Approved
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Cholic Acid.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be decreased when it is combined with Cholic Acid.Approved
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Cholic Acid.Approved
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesA05AA03
AHFS Codes
  • 56:92
PDB Entries
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9766
Blood Brain Barrier+0.9288
Caco-2 permeable+0.73
P-glycoprotein substrateSubstrate0.6648
P-glycoprotein inhibitor INon-inhibitor0.8737
P-glycoprotein inhibitor IIInhibitor0.5368
Renal organic cation transporterNon-inhibitor0.8537
CYP450 2C9 substrateNon-substrate0.7818
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateSubstrate0.7407
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9456
CYP450 2D6 inhibitorNon-inhibitor0.9781
CYP450 2C19 inhibitorNon-inhibitor0.9707
CYP450 3A4 inhibitorNon-inhibitor0.8405
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9563
Ames testNon AMES toxic0.8794
CarcinogenicityNon-carcinogens0.9329
BiodegradationNot ready biodegradable0.992
Rat acute toxicity2.5624 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9622
hERG inhibition (predictor II)Non-inhibitor0.7246
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
CapsuleOral250 mg/1
CapsuleOral50 mg/1
CapsuleOral250 mg
CapsuleOral50 mg
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point198 °CPhysProp
water solubility175 mg/L (at 20 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP2.02RODA,A ET AL. (1990)
logS-3.37ADME Research, USCD
pKa4.98 (at 20 °C)SERJEANT,EP & DEMPSEY,B (1979)
Predicted Properties
PropertyValueSource
Water Solubility0.0738 mg/mLALOGPS
logP2.26ALOGPS
logP2.48ChemAxon
logS-3.7ALOGPS
pKa (Strongest Acidic)4.48ChemAxon
pKa (Strongest Basic)-0.16ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area97.99 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity110.79 m3·mol-1ChemAxon
Polarizability46.93 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Positivesplash10-00dl-0009000000-85abf6e916e1cc1c46b6View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Positivesplash10-00dl-0009000000-476dc71e401cc2327292View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Positivesplash10-00nb-2109000000-0181c85f78bb9e29ea53View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Negativesplash10-0a4r-0009700000-63a8d2c748b3bc631c17View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Negativesplash10-052r-1009200000-ba378537551be8134141View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Negativesplash10-0a4l-9006000000-caef890bd53da215442eView in MoNA
MSMass Spectrum (Electron Ionization)splash10-0596-9642000000-e425981b8a0ac72ea6eeView in MoNA
1D NMR13C NMR SpectrumNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as trihydroxy bile acids, alcohols and derivatives. These are prenol lipids structurally characterized by a bile acid or alcohol which bears three hydroxyl groups.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassBile acids, alcohols and derivatives
Direct ParentTrihydroxy bile acids, alcohols and derivatives
Alternative Parents
Substituents
  • Trihydroxy bile acid, alcohol, or derivatives
  • 7-hydroxysteroid
  • 3-alpha-hydroxysteroid
  • Hydroxysteroid
  • 12-hydroxysteroid
  • 3-hydroxysteroid
  • Cyclic alcohol
  • Secondary alcohol
  • Polyol
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Alcohol
  • Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Iron-responsive element binding
Specific Function:
Catalyzes the ferrous insertion into protoporphyrin IX.
Gene Name:
FECH
Uniprot ID:
P22830
Molecular Weight:
47861.77 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Zinc ion binding
Specific Function:
Not Available
Gene Name:
ADH1C
Uniprot ID:
P00326
Molecular Weight:
39867.27 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Zinc ion binding
Specific Function:
Orphan receptor that acts as transcription activator in the absence of bound ligand. Binds specifically to an estrogen response element and activates reporter genes controlled by estrogen response elements (By similarity). Induces the expression of PERM1 in the skeletal muscle.
Gene Name:
ESRRG
Uniprot ID:
P62508
Molecular Weight:
51305.485 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Transporter activity
Specific Function:
Ileal protein which stimulates gastric acid and pepsinogen secretion. Seems to be able to bind to bile salts and bilirubins. Isoform 2 is essential for the survival of colon cancer cells to bile acid-induced apoptosis.
Gene Name:
FABP6
Uniprot ID:
P51161
Molecular Weight:
14371.245 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Cytochrome-c oxidase activity
Specific Function:
This protein is one of the nuclear-coded polypeptide chains of cytochrome c oxidase, the terminal oxidase in mitochondrial electron transport.
Gene Name:
COX4I1
Uniprot ID:
P13073
Molecular Weight:
19576.6 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Iron ion binding
Specific Function:
Cytochrome c oxidase is the component of the respiratory chain that catalyzes the reduction of oxygen to water. Subunits 1-3 form the functional core of the enzyme complex. CO I is the catalytic subunit of the enzyme. Electrons originating in cytochrome c are transferred via the copper A center of subunit 2 and heme A of subunit 1 to the bimetallic center formed by heme A3 and copper B.
Gene Name:
MT-CO1
Uniprot ID:
P00395
Molecular Weight:
57040.91 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Cytochrome-c oxidase activity
Specific Function:
Cytochrome c oxidase is the component of the respiratory chain that catalyzes the reduction of oxygen to water. Subunits 1-3 form the functional core of the enzyme complex. Subunit 2 transfers the electrons from cytochrome c via its binuclear copper A center to the bimetallic center of the catalytic subunit 1.
Gene Name:
MT-CO2
Uniprot ID:
P00403
Molecular Weight:
25564.73 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Cytochrome-c oxidase activity
Specific Function:
Subunits I, II and III form the functional core of the enzyme complex.
Gene Name:
MT-CO3
Uniprot ID:
P00414
Molecular Weight:
29950.6 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Metal ion binding
Specific Function:
This is the heme A-containing chain of cytochrome c oxidase, the terminal oxidase in mitochondrial electron transport.
Gene Name:
COX5A
Uniprot ID:
P20674
Molecular Weight:
16761.985 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Metal ion binding
Specific Function:
This protein is one of the nuclear-coded polypeptide chains of cytochrome c oxidase, the terminal oxidase in mitochondrial electron transport.
Gene Name:
COX5B
Uniprot ID:
P10606
Molecular Weight:
13695.57 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Cytochrome-c oxidase activity
Specific Function:
This protein is one of the nuclear-coded polypeptide chains of cytochrome c oxidase, the terminal oxidase in mitochondrial electron transport.
Gene Name:
COX6C
Uniprot ID:
P09669
Molecular Weight:
8781.36 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Cytochrome-c oxidase activity
Specific Function:
This protein is one of the nuclear-coded polypeptide chains of cytochrome c oxidase, the terminal oxidase in mitochondrial electron transport. Plays a role in proper central nervous system (CNS) development in vertebrates.
Gene Name:
COX7B
Uniprot ID:
P24311
Molecular Weight:
9160.485 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Cytochrome-c oxidase activity
Specific Function:
This protein is one of the nuclear-coded polypeptide chains of cytochrome c oxidase, the terminal oxidase in mitochondrial electron transport.
Gene Name:
COX7C
Uniprot ID:
P15954
Molecular Weight:
7245.45 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Cytochrome-c oxidase activity
Specific Function:
This protein is one of the nuclear-coded polypeptide chains of cytochrome c oxidase, the terminal oxidase in mitochondrial electron transport.
Gene Name:
COX8A
Uniprot ID:
P10176
Molecular Weight:
7579.0 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Cytochrome-c oxidase activity
Specific Function:
This protein is one of the nuclear-coded polypeptide chains of cytochrome c oxidase, the terminal oxidase in mitochondrial electron transport.
Gene Name:
COX6A2
Uniprot ID:
Q02221
Molecular Weight:
10815.32 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Cytochrome-c oxidase activity
Specific Function:
Connects the two COX monomers into the physiological dimeric form.
Gene Name:
COX6B1
Uniprot ID:
P14854
Molecular Weight:
10192.345 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Cytochrome-c oxidase activity
Specific Function:
This protein is one of the nuclear-coded polypeptide chains of cytochrome c oxidase, the terminal oxidase in mitochondrial electron transport.
Gene Name:
COX7A1
Uniprot ID:
P24310
Molecular Weight:
9117.44 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Receptor binding
Specific Function:
PA2 catalyzes the calcium-dependent hydrolysis of the 2-acyl groups in 3-sn-phosphoglycerides, this releases glycerophospholipids and arachidonic acid that serve as the precursors of signal molecules.
Gene Name:
PLA2G1B
Uniprot ID:
P04054
Molecular Weight:
16359.535 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Triglyceride lipase activity
Specific Function:
Involved in the detoxification of xenobiotics and in the activation of ester and amide prodrugs. Hydrolyzes aromatic and aliphatic esters, but has no catalytic activity toward amides or a fatty acyl-CoA ester. Hydrolyzes the methyl ester group of cocaine to form benzoylecgonine. Catalyzes the transesterification of cocaine to form cocaethylene. Displays fatty acid ethyl ester synthase activity,...
Gene Name:
CES1
Uniprot ID:
P23141
Molecular Weight:
62520.62 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Ferrochelatase activity
Specific Function:
Catalyzes the ferrous insertion into protoporphyrin IX.
Gene Name:
DKFZp686P18130
Uniprot ID:
Q7KZA3
Molecular Weight:
47131.925 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Clostridium perfringens (strain 13 / Type A)
Pharmacological action
unknown
General Function:
Choloylglycine hydrolase activity
Specific Function:
The enzyme catalyzes the degradation of conjugated bile acids in the mammalian gut.
Gene Name:
cbh
Uniprot ID:
P54965
Molecular Weight:
37185.0 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Phospholipid binding
Specific Function:
Plays a role in lipoprotein-mediated cholesterol uptake in hepatocytes (PubMed:25732850). Binds cholesterol (PubMed:25732850). Binds free fatty acids and their coenzyme A derivatives, bilirubin, and some other small molecules in the cytoplasm. May be involved in intracellular lipid transport (By similarity).
Gene Name:
FABP1
Uniprot ID:
P07148
Molecular Weight:
14208.34 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Transporter activity
Specific Function:
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name:
ABCB11
Uniprot ID:
O95342
Molecular Weight:
146405.83 Da
References
  1. Hartmann G, Cheung AK, Piquette-Miller M: Inflammatory cytokines, but not bile acids, regulate expression of murine hepatic anion transporters in endotoxemia. J Pharmacol Exp Ther. 2002 Oct;303(1):273-81. [PubMed:12235261 ]
  2. Green RM, Hoda F, Ward KL: Molecular cloning and characterization of the murine bile salt export pump. Gene. 2000 Jan 4;241(1):117-23. [PubMed:10607905 ]
  3. Mita S, Suzuki H, Akita H, Stieger B, Meier PJ, Hofmann AF, Sugiyama Y: Vectorial transport of bile salts across MDCK cells expressing both rat Na+-taurocholate cotransporting polypeptide and rat bile salt export pump. Am J Physiol Gastrointest Liver Physiol. 2005 Jan;288(1):G159-67. Epub 2004 Aug 5. [PubMed:15297262 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Fickert P, Zollner G, Fuchsbichler A, Stumptner C, Pojer C, Zenz R, Lammert F, Stieger B, Meier PJ, Zatloukal K, Denk H, Trauner M: Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver. Gastroenterology. 2001 Jul;121(1):170-83. [PubMed:11438506 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Transporter activity
Specific Function:
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotrexate, antiviral drugs and other xenobiotics. Confers resistance to anticancer drugs. Hydrolyzes ATP with low efficiency.
Gene Name:
ABCC1
Uniprot ID:
P33527
Molecular Weight:
171589.5 Da
References
  1. Hartmann G, Cheung AK, Piquette-Miller M: Inflammatory cytokines, but not bile acids, regulate expression of murine hepatic anion transporters in endotoxemia. J Pharmacol Exp Ther. 2002 Oct;303(1):273-81. [PubMed:12235261 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibited by the grapefruit juice component naringin.
Gene Name:
SLCO1A2
Uniprot ID:
P46721
Molecular Weight:
74144.105 Da
References
  1. Fickert P, Zollner G, Fuchsbichler A, Stumptner C, Pojer C, Zenz R, Lammert F, Stieger B, Meier PJ, Zatloukal K, Denk H, Trauner M: Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver. Gastroenterology. 2001 Jul;121(1):170-83. [PubMed:11438506 ]
  2. Kullak-Ublick GA, Hagenbuch B, Stieger B, Schteingart CD, Hofmann AF, Wolkoff AW, Meier PJ: Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology. 1995 Oct;109(4):1274-82. [PubMed:7557095 ]
  3. Kullak-Ublick GA, Hagenbuch B, Stieger B, Wolkoff AW, Meier PJ: Functional characterization of the basolateral rat liver organic anion transporting polypeptide. Hepatology. 1994 Aug;20(2):411-6. [PubMed:8045503 ]
  4. Kanai N, Lu R, Bao Y, Wolkoff AW, Schuster VL: Transient expression of oatp organic anion transporter in mammalian cells: identification of candidate substrates. Am J Physiol. 1996 Feb;270(2 Pt 2):F319-25. [PubMed:8779893 ]
  5. Hata S, Wang P, Eftychiou N, Ananthanarayanan M, Batta A, Salen G, Pang KS, Wolkoff AW: Substrate specificities of rat oatp1 and ntcp: implications for hepatic organic anion uptake. Am J Physiol Gastrointest Liver Physiol. 2003 Nov;285(5):G829-39. Epub 2003 Jul 3. [PubMed:12842829 ]
  6. Jacquemin E, Hagenbuch B, Stieger B, Wolkoff AW, Meier PJ: Expression cloning of a rat liver Na(+)-independent organic anion transporter. Proc Natl Acad Sci U S A. 1994 Jan 4;91(1):133-7. [PubMed:8278353 ]
  7. Kouzuki H, Suzuki H, Ito K, Ohashi R, Sugiyama Y: Contribution of organic anion transporting polypeptide to uptake of its possible substrates into rat hepatocytes. J Pharmacol Exp Ther. 1999 Feb;288(2):627-34. [PubMed:9918568 ]
  8. Eckhardt U, Schroeder A, Stieger B, Hochli M, Landmann L, Tynes R, Meier PJ, Hagenbuch B: Polyspecific substrate uptake by the hepatic organic anion transporter Oatp1 in stably transfected CHO cells. Am J Physiol. 1999 Apr;276(4 Pt 1):G1037-42. [PubMed:10198348 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Bile acid:sodium symporter activity
Specific Function:
Plays a critical role in the sodium-dependent reabsorption of bile acids from the lumen of the small intestine. Plays a key role in cholesterol metabolism.
Gene Name:
SLC10A2
Uniprot ID:
Q12908
Molecular Weight:
37713.405 Da
References
  1. Fickert P, Zollner G, Fuchsbichler A, Stumptner C, Pojer C, Zenz R, Lammert F, Stieger B, Meier PJ, Zatloukal K, Denk H, Trauner M: Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver. Gastroenterology. 2001 Jul;121(1):170-83. [PubMed:11438506 ]
  2. Craddock AL, Love MW, Daniel RW, Kirby LC, Walters HC, Wong MH, Dawson PA: Expression and transport properties of the human ileal and renal sodium-dependent bile acid transporter. Am J Physiol. 1998 Jan;274(1 Pt 1):G157-69. [PubMed:9458785 ]
  3. Saeki T, Matoba K, Furukawa H, Kirifuji K, Kanamoto R, Iwami K: Characterization, cDNA cloning, and functional expression of mouse ileal sodium-dependent bile acid transporter. J Biochem. 1999 Apr;125(4):846-51. [PubMed:10101301 ]
  4. Saeki T, Takahashi N, Kanamoto R, Iwami K: Characterization of cloned mouse Na+/taurocholate cotransporting polypeptide by transient expression in COS-7 cells. Biosci Biotechnol Biochem. 2002 May;66(5):1116-8. [PubMed:12092825 ]
  5. Walters HC, Craddock AL, Fusegawa H, Willingham MC, Dawson PA: Expression, transport properties, and chromosomal location of organic anion transporter subtype 3. Am J Physiol Gastrointest Liver Physiol. 2000 Dec;279(6):G1188-200. [PubMed:11093941 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
References
  1. Fickert P, Zollner G, Fuchsbichler A, Stumptner C, Pojer C, Zenz R, Lammert F, Stieger B, Meier PJ, Zatloukal K, Denk H, Trauner M: Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver. Gastroenterology. 2001 Jul;121(1):170-83. [PubMed:11438506 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostaglandin E2, thromboxane B2, leukotriene C3, leukotriene E4, thyroxine and triiodothyronine. Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B1
Uniprot ID:
Q9Y6L6
Molecular Weight:
76447.99 Da
References
  1. Hartmann G, Cheung AK, Piquette-Miller M: Inflammatory cytokines, but not bile acids, regulate expression of murine hepatic anion transporters in endotoxemia. J Pharmacol Exp Ther. 2002 Oct;303(1):273-81. [PubMed:12235261 ]
  2. Konig J, Cui Y, Nies AT, Keppler D: A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J Physiol Gastrointest Liver Physiol. 2000 Jan;278(1):G156-64. [PubMed:10644574 ]
  3. Cui Y, Konig J, Leier I, Buchholz U, Keppler D: Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J Biol Chem. 2001 Mar 30;276(13):9626-30. Epub 2000 Dec 27. [PubMed:11134001 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Organic anion transmembrane transporter activity
Specific Function:
May act as an inducible transporter in the biliary and intestinal excretion of organic anions. Acts as an alternative route for the export of bile acids and glucuronides from cholestatic hepatocytes (By similarity).
Gene Name:
ABCC3
Uniprot ID:
O15438
Molecular Weight:
169341.14 Da
References
  1. Hirohashi T, Suzuki H, Takikawa H, Sugiyama Y: ATP-dependent transport of bile salts by rat multidrug resistance-associated protein 3 (Mrp3). J Biol Chem. 2000 Jan 28;275(4):2905-10. [PubMed:10644759 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Atpase activity, coupled to transmembrane movement of substances
Specific Function:
May be an organic anion pump relevant to cellular detoxification.
Gene Name:
ABCC4
Uniprot ID:
O15439
Molecular Weight:
149525.33 Da
References
  1. Rius M, Nies AT, Hummel-Eisenbeiss J, Jedlitschky G, Keppler D: Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane. Hepatology. 2003 Aug;38(2):374-84. [PubMed:12883481 ]
  2. Bai J, Lai L, Yeo HC, Goh BC, Tan TM: Multidrug resistance protein 4 (MRP4/ABCC4) mediates efflux of bimane-glutathione. Int J Biochem Cell Biol. 2004 Feb;36(2):247-57. [PubMed:14643890 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Virus receptor activity
Specific Function:
The hepatic sodium/bile acid uptake system exhibits broad substrate specificity and transports various non-bile acid organic compounds as well. It is strictly dependent on the extracellular presence of sodium.(Microbial infection) Acts as a receptor for hepatitis B virus.
Gene Name:
SLC10A1
Uniprot ID:
Q14973
Molecular Weight:
38118.64 Da
References
  1. Hagenbuch B, Stieger B, Foguet M, Lubbert H, Meier PJ: Functional expression cloning and characterization of the hepatocyte Na+/bile acid cotransport system. Proc Natl Acad Sci U S A. 1991 Dec 1;88(23):10629-33. [PubMed:1961729 ]
  2. Schroeder A, Eckhardt U, Stieger B, Tynes R, Schteingart CD, Hofmann AF, Meier PJ, Hagenbuch B: Substrate specificity of the rat liver Na(+)-bile salt cotransporter in Xenopus laevis oocytes and in CHO cells. Am J Physiol. 1998 Feb;274(2 Pt 1):G370-5. [PubMed:9486191 ]
  3. Hata S, Wang P, Eftychiou N, Ananthanarayanan M, Batta A, Salen G, Pang KS, Wolkoff AW: Substrate specificities of rat oatp1 and ntcp: implications for hepatic organic anion uptake. Am J Physiol Gastrointest Liver Physiol. 2003 Nov;285(5):G829-39. Epub 2003 Jul 3. [PubMed:12842829 ]
  4. Mita S, Suzuki H, Akita H, Stieger B, Meier PJ, Hofmann AF, Sugiyama Y: Vectorial transport of bile salts across MDCK cells expressing both rat Na+-taurocholate cotransporting polypeptide and rat bile salt export pump. Am J Physiol Gastrointest Liver Physiol. 2005 Jan;288(1):G159-67. Epub 2004 Aug 5. [PubMed:15297262 ]
  5. Platte HD, Honscha W, Schuh K, Petzinger E: Functional characterization of the hepatic sodium-dependent taurocholate transporter stably transfected into an immortalized liver-derived cell line and V79 fibroblasts. Eur J Cell Biol. 1996 May;70(1):54-60. [PubMed:8738419 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenadine. Transports benzylpenicillin (PCG), estrone-3-sulfate (E1S), cimetidine (CMD), 2,4-dichloro-phenoxyacetate (2,4-D), p-amino-hippurate (PAH), acyclovir (ACV) and ochratoxin (OTA).
Gene Name:
SLC22A8
Uniprot ID:
Q8TCC7
Molecular Weight:
59855.585 Da
References
  1. Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, Endou H: Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86. [PubMed:11306713 ]
  2. Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, Cha SH, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J Biol Chem. 1999 May 7;274(19):13675-80. [PubMed:10224140 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulfate, allopurinol, 5-fluorouracil, paclitaxel, L-ascorbic acid, salicylate, ethotrexate, and alpha-ketoglutarate.
Gene Name:
SLC22A7
Uniprot ID:
Q9Y694
Molecular Weight:
60025.025 Da
References
  1. Sekine T, Cha SH, Tsuda M, Apiwattanakul N, Nakajima N, Kanai Y, Endou H: Identification of multispecific organic anion transporter 2 expressed predominantly in the liver. FEBS Lett. 1998 Jun 12;429(2):179-82. [PubMed:9650585 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotrexate and sulfobromophthalein (BSP). Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B3
Uniprot ID:
Q9NPD5
Molecular Weight:
77402.175 Da
References
  1. Cui Y, Konig J, Leier I, Buchholz U, Keppler D: Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J Biol Chem. 2001 Mar 30;276(13):9626-30. Epub 2000 Dec 27. [PubMed:11134001 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23